Simona Halep appeals four-year competition ban over anti-doping violations
Posted : 24 October 2023
Former Wimbledon champion Simona Halep has initiated an appeal with the Court of Arbitration for Sport (CAS) in response to her four-year competition ban for violating anti-doping regulations. The 32-year-old two-time Grand Slam winner was penalized with the suspension by the International Tennis Integrity Agency (ITIA) in September.
The ITIA had cited two transgressions of the Tennis Anti-Doping Programme (TADP), specifically related to the presence and use of roxadustat in Halep's urine sample obtained on August 29, 2022, during the US Open, and the use of a prohibited substance or method throughout 2022 as identified through the analysis of 51 blood samples provided by the player under the Athlete Biological Passport (ABP) program.
A statement from CAS confirmed that they have received Halep's appeal and provided details about the ongoing proceedings. The tennis player seeks to challenge the decision of the ITIA Tribunal, which imposed the four-year ineligibility sanction starting on October 7, 2022, and the disqualification of all results and rewards earned during the period from August 29, 2022, to October 7, 2022, including medals, titles, ranking points, and prize money. CAS proceedings have already commenced, adhering to the CAS Code.
The arbitration rules governing CAS procedures are being followed, including the exchange of written submissions, and the formation of a panel of arbitrators that will oversee the case. Following these initial steps, a hearing will take place, and subsequently, the panel will issue a final decision.
The CAS Panel's determination will be binding and final, except for the possibility of the parties involved filing an appeal with the Swiss Federal Tribunal, subject to specific grounds, within 30 days. The timeline for the issuance of the decision remains undetermined at this stage.
ADD A COMMENT :
Hot Topics
User name is required Email Id is required Comment is required
ADD A COMMENT :